Company intelligence / Profile preview

Chengdu Kangnuoxang Biopharmaceutical Technology

Ownership: Private
Employees: ~4462
Development stage: Commercial

Overview

Conbercept/Lumitin has been approved and marketed in China since at least late 2013 for retinal diseases. It has completed pivotal global Phase III studies with positive results expected to support international approvals. Additional pipeline assets include next-generation antibodies and ADCs targeting oncology and ophthalmology indications.

Therapeutic areas: OncologyOncology, EndocrinologyOtherCardiovascularOphthalmology
Modalities: Antibody fusion proteins (e.g., conbercept)Small molecules (various drugs for CNS, digestive, endocrine)Dual payload antibody-drug conjugates (ADC)Herbal medicines
Industry: Biotech

Partnerships

Distribution partnership with IOPtima/BioLight Israeli Life Sciences Investmentcollaborations with >300 research institutions globally for clinical trials of conbercept/Lumitin.

Beyond the preview

Go deeper on Chengdu Kangnuoxang Biopharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Kangnuoxang Biopharmaceutical Technology.

Explore the full profile